MAP2K7 and hepatocellular carcinoma: This result suggests that inhibition of MEK signaling alone is not sufficient to successfully treat advanced-stage HCC, therefore two clinical trials are currently testing AZD6244 in HCC patients with less severe disease, i.e. moderate liver dysfunction, and also in association with sorafenib (Table 1).